Verona Pharma updates on RPL554 clinical trial
Verona Pharma's shares are up more than 1% after it confirmed the first patient had been dosed in its Phase 2a clinical trial evaluating RPL554 in the treatment of chronic obstructive pulmonary disease (COPD).
FTSE AIM All-Share
737.78
10:10 07/10/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,130.28
10:09 07/10/24
0.10%
22.04
Verona Pharma
55.00p
16:55 29/10/20
5.77%
3.00p
RPL554 was being used as an add-on therapy to tiotropium (Spiriva), a commonly used long-acting bronchodilator. Top-line data from the trial was expected in 4Q 2017.
At 10:43 GMT, shares in AIM-priced Verona were up 1.2% to 126.5p each.